Literature DB >> 22736748

Increased hospitalizations and death in patients with ESRD secondary to lupus.

S Sule1, B Fivush, A Neu, S Furth.   

Abstract

BACKGROUND: Systemic lupus erythematosus (SLE) is an autoimmune disease that can affect almost any organ system, including the kidneys. Using a large national dataset, our goal was to compare the morbidity as measured by hospitalization and mortality rates between hemodialysis patients with end-stage renal disease (ESRD) secondary to SLE to those with ESRD due to other causes.
METHODS: The risk of hospitalization was calculated by Poisson regression with clustering for repeated measures using the United States Renal Data System (USRDS) Hospitalization Analytic File in strata of pediatric and adult patients. Cox proportional hazard ratio was used to assess the mortality risk in hospitalized patients. Subjects were censored at transplantation or end of follow-up.
RESULTS: Adult patients with ESRD secondary to SLE were hospitalized more frequently than other adults (incidence rate ratio (IRR): 1.43, 95% confidence interval (CI): 1.15-1.77) and had a higher risk of death (hazard ratio (HR): 1.89, 95% CI: 1.66-2.5). Mortality was higher in hospitalized pediatric patients with SLE compared to pediatric patients with other causes of ESRD (HR: 2.01, 95% CI: 1.75-2.31) and adults with SLE (HR: 2.05, 95% CI: 1.79-2.34).
CONCLUSION: Our study demonstrates that there is a trend toward increased hospitalization rates in pediatric and adult patients with SLE. Among these hospitalized patients with SLE, there is an increased risk of death due to cardiovascular disease.

Entities:  

Mesh:

Year:  2012        PMID: 22736748      PMCID: PMC4906535          DOI: 10.1177/0961203312451506

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  18 in total

Review 1.  Prevalence and burden of pediatric-onset systemic lupus erythematosus.

Authors:  Sylvia Kamphuis; Earl D Silverman
Journal:  Nat Rev Rheumatol       Date:  2010-08-03       Impact factor: 20.543

2.  Hospitalization and mortality of patients with systemic lupus erythematosus.

Authors:  Eswar Krishnan
Journal:  J Rheumatol       Date:  2006-07-01       Impact factor: 4.666

3.  Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis.

Authors:  M T Grattan; C E Moreno-Cabral; V A Starnes; P E Oyer; E B Stinson; N E Shumway
Journal:  JAMA       Date:  1989 Jun 23-30       Impact factor: 56.272

4.  Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus.

Authors:  Mary J Roman; Beth-Ann Shanker; Adrienne Davis; Michael D Lockshin; Lisa Sammaritano; Ronit Simantov; Mary K Crow; Joseph E Schwartz; Stephen A Paget; Richard B Devereux; Jane E Salmon
Journal:  N Engl J Med       Date:  2003-12-18       Impact factor: 91.245

Review 5.  Update on pediatric systemic lupus erythematosus.

Authors:  Dorothee Stichweh; Edsel Arce; Virginia Pascual
Journal:  Curr Opin Rheumatol       Date:  2004-09       Impact factor: 5.006

6.  Lupus nephritis in childhood: a review of 53 patients followed at a single center.

Authors:  Radovan Bogdanović; Vesna Nikolić; Srdjan Pasić; Jovan Dimitrijević; Jasmina Lipkovska-Marković; Jelena Erić-Marinković; Milos Ognjanović; Aleksandra Minić; Natasa Stajić
Journal:  Pediatr Nephrol       Date:  2003-11-22       Impact factor: 3.714

7.  Changing patterns in mortality and disease outcomes for patients with systemic lupus erythematosus.

Authors:  Murray B Urowitz; Dafna D Gladman; Brian D M Tom; Dominique Ibañez; Vernon T Farewell
Journal:  J Rheumatol       Date:  2008-09-15       Impact factor: 4.666

8.  Risk factors for coronary artery disease in patients with systemic lupus erythematosus.

Authors:  M Petri; S Perez-Gutthann; D Spence; M C Hochberg
Journal:  Am J Med       Date:  1992-11       Impact factor: 4.965

Review 9.  The epidemiology of systemic lupus erythematosus.

Authors:  Sònia Jiménez; Ricard Cervera; Josep Font; Miguel Ingelmo
Journal:  Clin Rev Allergy Immunol       Date:  2003-08       Impact factor: 8.667

10.  Increased arterial stiffness correlated with disease activity in systemic lupus erythematosus.

Authors:  Q Shang; L S Tam; E K M Li; G W K Yip; C M Yu
Journal:  Lupus       Date:  2008-12       Impact factor: 2.911

View more
  8 in total

1.  Validation of Systemic Lupus Erythematosus Diagnosis as the Primary Cause of Renal Failure in the US Renal Data System.

Authors:  Anna Broder; Wenzhu B Mowrey; Peter Izmirly; Karen H Costenbader
Journal:  Arthritis Care Res (Hoboken)       Date:  2017-04       Impact factor: 4.794

Review 2.  Improving outcomes in patients with lupus and end-stage renal disease.

Authors:  Antonio Inda-Filho; Joel Neugarten; Chaim Putterman; Anna Broder
Journal:  Semin Dial       Date:  2013-09-04       Impact factor: 3.455

3.  Patient characteristics and outcomes by GN subtype in ESRD.

Authors:  Michelle M O'Shaughnessy; Maria E Montez-Rath; Richard A Lafayette; Wolfgang C Winkelmayer
Journal:  Clin J Am Soc Nephrol       Date:  2015-06-19       Impact factor: 8.237

4.  Incidence of End-Stage Renal Disease Among Newly Diagnosed Systemic Lupus Erythematosus Patients: The Georgia Lupus Registry.

Authors:  Laura Plantinga; S Sam Lim; Rachel Patzer; William McClellan; Michael Kramer; Mitchel Klein; Stephen Pastan; Caroline Gordon; Charles Helmick; Cristina Drenkard
Journal:  Arthritis Care Res (Hoboken)       Date:  2016-03       Impact factor: 4.794

5.  Association between antiphospholipid antibodies and all-cause mortality among end-stage renal disease patients with and without SLE: a retrospective cohort study.

Authors:  Anna Broder; Wenzhu B Mowrey; Mimi Kim; Irina Murakhovskaya; Henny Billett; Joel Neugarten; Karen H Costenbader; Chaim Putterman
Journal:  Rheumatology (Oxford)       Date:  2015-12-24       Impact factor: 7.580

6.  Primary causes of kidney disease and mortality in dialysis-dependent children.

Authors:  Yusuke Okuda; Melissa Soohoo; Kenji Ishikura; Ying Tang; Yoshitsugu Obi; Marciana Laster; Connie M Rhee; Elani Streja; Kamyar Kalantar-Zadeh
Journal:  Pediatr Nephrol       Date:  2020-02-04       Impact factor: 3.714

7.  Prescribing Patterns of Hydroxychloroquine and Glucocorticoids Among Lupus Patients After New-Onset End-Stage Renal Disease.

Authors:  Anna Broder; Wenzhu B Mowrey; Ana Valle; Mimi Kim; Candace H Feldman; Kazuki Yoshida; Karen H Costenbader
Journal:  Arthritis Care Res (Hoboken)       Date:  2021-06-13       Impact factor: 5.178

8.  Systemic lupus Erythematosus activity and Hydroxychloroquine use before and after end-stage renal disease.

Authors:  Maria Salgado Guerrero; Alejandra Londono Jimenez; Chrisanna Dobrowolski; Wenzhu B Mowrey; Beatrice Goilav; Shudan Wang; Anna Broder
Journal:  BMC Nephrol       Date:  2020-10-28       Impact factor: 2.388

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.